We use cookies necessary to giving you a better online experience. By using our website you consent to all cookies in accordance with our Privacy Policy.
Yes, I accept
Menu
Search Opener

Session Item

Poster: Miscellaneous
Poster
World Congress of Brachytherapy 2021
00:00 - 00:00
Preventing Radioinduced Injury by Topical Application of an Amifostine Metabolite-Loaded Thermogel
PO-1803

Abstract

Preventing Radioinduced Injury by Topical Application of an Amifostine Metabolite-Loaded Thermogel
Authors: CLÉMENSON|, Céline(1)*[celine.clemenson@gustaveroussy.fr];Liu|, Winchygn(1);Bricout|, Denis(2);Soyez-Herkert|, Loren(1);Chargari|, Cyrus(3);Mondini|, Michele(1);Haddad|, Raphaël(2);Wang-Zang|, Xiuping(2);Benel|, Laurent(2);Bloy|, Christian(2);Deutsch|, Eric(4);
(1)Gustave Roussy, Inserm U1030, Villejuif, France;(2)CleveXel Pharma, Life Science, Paris, France;(3)Gustave Roussy, Radiotherapy Department, Villejuif, France;(4)Gustave Roussy, Inserm U1030 and Radiotherapy Department, Villejuif, France;
Show Affiliations
Purpose or Objective

Despite the development of high-precision radiation therapy, ionizing radiation inevitably damages healthy tissues. Radiodermatitis and radioinduced oral mucositis are frequent and significant side effects among patients with breast and head and neck cancer, respectively. These radiation-related injuries negatively affect patient quality of life and can lead to unplanned therapeutic breaks and compromise treatment outcomes. Currently, no preventive or mitigating agent has emerged to address these issues. Although amifostine, a well-known free radical scavenger, has proven efficacy against specific radio- and chemo-induced toxicities, severe adverse side effects (reversible hypotension, nausea, emesis, etc) combined with logistical hurdles are associated with its recommended intravenous route of administration, limiting its use.

Material and Methods

We developed a thermogel containing the active thiol metabolite of amifostine (CPh-1014) that polymerizes at body temperature and serves as a matrix for topical application onto the skin or mucosa. We evaluated its efficacy for the prevention of radiation-related toxicities, using mouse models of oral mucositis and radiodermatitis. We evaluated the orthostatic response to CPh-1014 in dogs.

Results

Applied before irradiation, CPh-1014 greatly reduced the severity of oral mucositis and dermatitis induced by either a single dose or fractionated irradiation regimens in in vivo mouse models. The cytoprotective effect of CPh-1014 was confirmed by the decrease in DNA double-strand breaks in the irradiated epithelium. Noticeably, CPh-1014 did not affect radiation therapy efficacy against tumors grafted at submucosal and subcutaneous sites. In contrast to the intravenous administration of amifostine, CPh-1014 oral application did not induce hypotension in dogs.

Conclusion

CPh-1014 confers radioprotective effects in healthy tissues with reduced systemic side effects without compromising radiation therapy efficacy. We propose CPh-1014 as an easy-to-implement therapeutic approach to alleviate radiation therapy toxicity in patients with breast and head and neck cancer.